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Objectives: Carbapenem-resistant Enterobacteriaceae isolates (n¼1485) were received at the French Associated
National Reference Center for Antibiotic Resistance in 2012 and were characterized for their mechanism of resist-
ance to carbapenems.
Methods: Carbapenemase productionwas detected using the biochemical-based CarbaNP test, based on the de-
tection of in vitro hydrolysis of imipenem. All isolateswith a positive Carba NP test result were characterized by PCR
and sequencing.
Results: Carbapenemase production was identified in 23.1% of the isolates. The main carbapenemase type
identified was OXA-48 and derivatives (75.5%). An overseas source was clearly demonstrated for only 27.6% of
the isolates.
Conclusions: OXA-48 and derivatives are now the most prevalent carbapenemases in France, with a possible
spread of these producers in the community.
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Introduction
During the last decade, Gram-negative clinical isolates, including
Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp.
with decreased susceptibility to carbapenems, have been increas-
ingly reported in Europe.1,2 Carbapenem resistance in Enterobac-
teriaceae may be related either to the association of a decrease
in bacterial outer-membrane permeability with overexpression of
b-lactamases possessing a very weak carbapenemase activity, or
to a b-lactamase with strong hydrolytic activity towards carbape-
nems, i.e. a carbapenemase.2Differentiationof thesemechanisms
may have consequences for the clinical management of patients
and prevention of nosocomial outbreaks.3–5 Themain carbapene-
mases described in Enterobacteriaceae are the Ambler class A KPC
enzymes,6 Ambler class B b-lactamases (metallo-b-lactamases)
of VIM, IMPand NDM types,2,7 and Ambler class D carbapenemases
of theOXA-48type.8Thecarbapenemase-producingEnterobacteria-
ceaeareusually resistanttomanyotherb-lactamandnon-b-lactam
antibiotics, giving rise to multiresistant and pandrug-resistant
isolates.
Methods
From January 2012 to December 2012, 1485 enterobacterial isolates were
received from all areas of France by the French Associated National Refer-
enceCenter for Antibiotic Resistance in order to test for carbapenemaseac-
tivity leading to reduced susceptibility to carbapenems. All isolates were
identified at the species level using a MALDI-TOF spectrometric identifica-
tion system (bioMe´rieux, La Balme-les-Grottes, France). Most of them
wereEnterobacter spp. (42.2%),Klebsiellapneumoniae (35.2%)andEscher-
ichia coli (12.7%). Susceptibilities to antibiotics, including carbapenems,
aminoglycosides, quinolones, tigecycline, fosfomycin, co-trimoxazole,
chloramphenicol and nitrofurantoin, were determined by disc diffusion on
Mueller–Hinton agar (Bio-Rad, Marnes-la-Coquette, France). According to
EUCAST breakpoints (www.eucast.org), most of the isolates were non-
susceptible to at least one of the three carbapenems for which MICs were
determined by Etest (bioMe´rieux) (imipenem, meropenem and ertapen-
em). Carbapenemase production was detected using the Carba NP test,
based on the detection of in vitro hydrolysis of imipenem demonstrated
by a chromogenic test.9 All isolates giving a positive Carba NP test result
were characterized by PCR aimed at identifying the main carbapenemase
genes described in Enterobacteriaceae: blaKPC, blaNDM, blaVIM, blaIMP, blaIMI
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Table 1. Geographical origins of carbapenemase-producing isolates
Carbapenemase type
OXA-48 OXA-162 OXA-181 OXA-204 KPC-2 KPC-3 NDM-1 NDM-4 NDM-5 NDM-7 VIM-1 VIM-2 VIM-4 IMI-1 IMI-2
Morocco 17
India 2 11 2
Turkey 3 1
Tunisia 11 1
Algeria 14
Lebanon 1
Libya 5
Egypt 1 1
China 1
Israel 2
Italy 3 2
Romania 1
Russia 1
Vietnam 1 1
Senegal 1
Kuwait 1 1
Brazil 1
Nepal 2
Seychelles 1
Middle East 1
Mali 1
Singapore 1
Burma 1
Mauritania 1
Linkage with foreign
country (%)
56 (22.6) 1 (33.3) 2 (100) 0 (0) 5 (20.8) 3 (20.0) 16 (76.2) 3 (75.0) 1 (100) 1 (100) 3 (42.9) 0 (0) 3 (100) 0 (0) 0 (0)
Unknown or no linkage
with foreign country (%)
192 (77.4) 2 (66.7) 0 (0) 4 (100) 19 (79.2) 12 (80.0) 5 (23.8) 1 (25.0) 0 (0) 0 (0) 4 (57.1) 6 (100) 0 (0) 1 (100) 1 (100)
Total 248 3 2 4 24 15 21 4 1 1 7 6 3 1 1
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Figure 1. Distribution of enterobacterial species of carbapenemase-producing (+) and non-carbapenemase-producing (2) isolates. (Left) Distribution of
OXA-48-like,NDM,KPC,VIMandIMIcarbapenemases foreachgroupofenterobacterial species. (Middle)Distributionofcarbapenemase-producing (+) and
non-carbapenemase-producing (2) isolates inenterobacterial species. (Right)Distributionofnon-carbapenemasemechanisms responsible fordecreased
carbapenem susceptibility in enterobacterial species: impermeability (imp), ESBL+ impermeability, cephalosporinase (Case)+ impermeability and
ESBL+cephalosporinase+ impermeability. Carbapenem-susceptible isolates (after MIC confirmation) are also shown. Numbers correspond to the
numbers of isolates. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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and blaOXA-48. PCR amplicons were subsequently sequenced.
3 Decreased
carbapenem susceptibility due to overexpression of a cephalosporinase
(chromosome encoded or plasmid acquired) was suspected for
isolates (i) having carbapenem susceptibility restored on cloxacillin-
supplemented (200 mg/L) Mueller–Hinton agar and (ii) being negative
in the Carba NP test. Additionally, growth on cloxacillin-supplemented
medium led to the detection of extended-spectrumb-lactamase (ESBL)-
producing isolates that also produce a cephalosporinase at a high level.
ESBL production was demonstrated by double disc synergy testing
between extended-spectrum cephalosporins (cefotaxime, ceftazidime,
cefepime and aztreonam) and clavulanate (ticarcillin/clavulanic acid),
performed on Mueller–Hinton agar and cloxacillin-supplemented
Mueller–Hinton agar.
Results
Among the1485 tested isolates, 341 (22.9%)producedacarbape-
nemase. These carbapenemases were OXA-48 like (75.4%), KPC
(11.4%), NDM (7.9%), VIM (4.7%) and IMI (0.6%) (Table 1). Most
of the carbapenemase producers were K. pneumoniae isolates
(65.9%), which are mostly nosocomial pathogens. Additionally,
another group of nosocomial pathogens, Enterobacter species,
represented 9.7% of the carbapenemase producers. Therefore,
the spread of carbapenemase-producing Enterobacteriaceae
was mainly associated with hospital dissemination in France.
However, several E. coli isolates were identified among the
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Figure 2. (a) Determination of linkagewith a cross-border country for patients infected or colonizedwith carbapenemase-producing Enterobacteriaceae.
(b) Distribution of specimens from which carbapenemase producers were recovered.
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carbapenemase producers (15.5%). Since their nosocomial acqui-
sition could not be clearly established, dissemination of these
strains in the community remains possible. All carbapenemase
producers expressed a single carbapenemase type except one
isolate of K. pneumoniae that was positive for NDM-1 and
OXA-181 (an OXA-48 variant). Regardless of the enterobacterial
species, OXA-48-like carbapenemases were predominant (76.8%
of carbapenemase-producing K. pneumoniae, 81.1% of
carbapenemase-producing E. coli, 75.8% of carbapenemase-
producing Enterobacter spp., 53.3% of carbapenemase producers
among the other enterobacterial species) (Figure 1). Like OXA-48
producers, NDM producers were equally distributed among the
groups of bacterial species (P.0.05, x2 test) (Figure 1). Conversely,
KPC producers (95%, P,0.001, x2 test) were significantly more
represented inK. pneumoniae comparedwith theotherenterobac-
terial species (37 K. pneumoniae, 1E. coliand1Citrobacter freundii).
The main species associated with VIM carbapenemases was C.
freundii (62.5%), but this result is biased by the clonal dissemin-
ation of a single VIM-positive isolate in the same hospital. The
IMI producers (n¼2) were Enterobacter spp. (1 Enterobacter
asburiae and 1 Enterobacter cloacae).
In the absence of carbapenemase production, the decreased
susceptibility to carbapenems was explained by decreased outer
membrane permeability associated with the expression of a
b-lactamase with weak hydrolytic activity against carbapenems.
ESBL production was mostly detected in K. pneumoniae (75.2%)
and E. coli (66.7%), whereas, as expected, overexpression of the
chromosome-encoded cephalosporinase was mainly involved in
Enterobacter spp. (68.2%) (Figure 1).
A probable linkwith a foreign countrywas established for 27.6%
(94/341) of patients infected or colonized with a carbapenemase
producer (Table 1). This link with a cross-border country was
clearly identified for NDM producers (Table 1). Indeed, most of the
NDM-producing isolates (77.8%) were related to the Indian sub-
continent, which is known to be the main reservoir of metallo-
b-lactamase.7 Of note, several strains were isolated on Re´union
island, indicating that this French territory (near to Madagascar)
is the most exposed for NDM dissemination. The KPC-producing
strains were often recovered from patients previously hospitalized
in Italyand Israel, twocountrieswhereKPCproducersarewidelydis-
seminated.6 Curiously, despite the economic and social relation-
ships between Greece and France, no KPC-producing isolate was
recovered frompatients having linkswith Greece, where KPC produ-
cers are endemic. Of the 56 OXA-48 producers with an established
link with a foreign country, 48 (85.7%) were related to North
African countries, and all OXA-181 producers were related to
India. These results are in agreement with the epidemiological
data known about OXA-48 and its variants.8,10 The fact that
OXA-48 and derivatives are now the most prevalent carbapene-
mases in France is related to the large population exchange with
NorthAfricancountries.However, aclear linkagewithacross-border
country has been reported for only 29.9%ofOXA-48-like producers,
indicating a possible spread of OXA-48 producers in the community
in France.
Among the 341 carbapenemase-producing isolates, 204
(59.8%) were isolated from rectal swabs and 137 (40.2%) were
from clinical samples (Figure 2). These percentages were similar
for all carbapenemase types. Of note, 43.1% (97/225) of the
carbapenemase-producing K. pneumoniae were from clinical
samples. This frequency was significantly higher (P,0.05, Stu-
dent’s t-test) than that observed for carbapenemase-producing
E. coli (28.3%).
Discussion
Carbapenem resistance in Enterobacteriaceae isolates from
France has been increasing since 2005 (data not shown). Analysis
of 1485 carbapenem-resistant isolates isolated in 2012 high-
lighted several concerns. (i) The two main organisms with
decreased susceptibility to carbapenems are K. pneumoniae and
Enterobacter spp. However, a major difference was observed
between these two groups: 43% of K. pneumoniae isolates
produced a carbapenemase, whereas only 5.3% of Enterobacter
spp. did so. (ii) The main carbapenemase identified was OXA-48,
which could be linked in part to dissemination in the community.
The Carba NP test has been shown to be a powerful technique
to discriminate rapidly between carbapenemase and non-
carbapenemase producers.
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